STOCKS TELEGRAPH

Tag: KTRA Stock Price

  • Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) has seen decrease of 1.13% in the premarket despite any news reported by the company. However, the last trading session closed at $0.354 with a decrease of 10.27%.

    Multiyear Research Grant – What’s up?

    KTRA announced on 12th January 2022 that Doctor Anna Golebiewska has been awarded with a multiyear research grant. This research grant is awarded by Luxembourg National Research Fund (FNR) and the Cancer Foundation Luxembourg. In Luxembourg, the FNR is the primary source of funding for research. Moreover, the Cancer Foundation Luxembourg is committed to patient assistance and oncology research by educating cancer patients.

    Now what?

    The acknowledgement and economic assistance from this prestigious organisation for VAL-083 research in Dr. Golebiewska’s laboratory is extremely exciting because it will offer critical data for optimising the clinical use of this first-in-class specific molecular chemotherapeutic. Furthermore, the findings of this study will aid in elucidating possible therapeutic targets for novel co – treatment regimens involving VAL-083, as well as promote the chance to improve therapeutic accuracy in GBM patients.

    First International Site Activation by KTRA – More About it

    On 30th November 2021, KTRA reported about the site activation in GCAR Phase 2/3 Clinical Trial. The speed with which the treatment arm will be implemented in the research continues to excite the Kintara team. Not only this but the company is thrilled to witness GCAR’s outstanding clinical testing consequences, which drew the team to participate in this exciting and highly efficient registrational study. With 31 sites already operational, including the first international site, the company is hopeful to observe GCAR’s extraordinary clinical trial execution capabilities.

    Through response adaptive randomization and a seamless Phase 2/3 design, GBM AGILE is a multinational, novel platform study that aims to find and confirm beneficial medicines for patients with GBM more quickly. The trial will be run under a master protocol that allows numerous medicines. Data from GBM AGILE might be utilized as the basis for new drug applicants and biologics licence applications. This has only been possible because of its novel design and efficient operational infrastructure.

  • What Do You Think Has Boosted KTRA Stock This Morning?

    As of the last check, shares of biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, Kintara Therapeutics Inc. (KTRA) were trading at $2.80, an increase of 23.35%. Kintara stock closed at $2.27 in the previous session. Volume for KTRA stock remained at 4.81 million shares, which is above the past 50 days’ average of 1.15 million shares.

    In the past week, KTRA shares have gained 1.34%, with this year’s performance of 230.04%. During a three-month period, KTRA stock gained 30.46%, and over a six-month period, it gained 71.97%. Additionally, KTRA has a current market capitalization of $74.68 million and still has 29.27 million outstanding shares. Following topline results from a phase 2 clinical trial, KTRA stock has been rising.

    Why did KTRA conduct the trial?

    Kintara, which has its headquarters in San Diego, California, focuses on the development of novel cancer therapies. In addition to VAL-083, KTRA is developing REM-001 for cutaneous metastatic breast cancer (CMBC), both of which are Phase 3-ready. A novel blood-brain barrier crossing, small molecule, bifunctional alkylating agent by KRTA, called VAL-083, has shown clinical activity against a variety of cancers. KTRA’s proprietary, late-stage photodynamic therapy platform, REM-001, demonstrates promise for localized cutaneous tumor treatment and for other potential applications.

    In its open-label, Phase 2 clinical study of its lead compound VAL-083, Kintara today announced topline data results from the recurrent arm.

    • The study was conducted by KTRA at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.
    • In Phase 2 of KTRA’s study, the treatment will be tested in patients with the unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene in glioblastoma multiforme (GBM) patients.
    • In the recurrent arm of the KTRA study, temozolomide was pre-treated prior to disease recurrence in patients with temozolomide pre-treatment.
    • A total of 89 patients were enrolled at KTRA, who were initially treated with 30 mg/m2/day on days 1, 2, and 3 of a 21-day cycle.
    • The 30 mg dose being examined is the same dose being tested in KTRA’s recently initiated and currently enrolling GBM AGILE study arm, VAL-083.

    An overview of the results:

    • The median overall survival (mOS) of the 48 efficacy-evaluable patients initially treated with 30 mg / m2 / day was found to be 8.0 months in the KTRA study.
    • Similary to KTRA’s prior research, the most frequent adverse event was myelosuppression.
    • Among patients receiving VAL-083 at 30 mg/m2/day, five experienced a serious adverse event (SAE) possibly related to the drug.
    • KTRA observed that mOS was 7.5 months for 83 efficacy evaluable patients who had completed at least one cycle of treatment.

    The FDA and European Medicines Agency have granted KTRA’s VAL-083 an Orphan Drug Designation for GBM. The FDA has also authorized Kintara (KTRA) to use it for the treatment of medulloblastoma and ovarian cancer, granting it Orphan Drug Designation for the same. Furthermore, KTRA’s VAL-083 in recurrent GBM has been given Fast Track Designation by the FDA.